Bbva Compass Bancshares Inc. trimmed its holdings in shares of AbbVie Inc (NYSE:ABBV) by 2.5% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 32,515 shares of the company’s stock after selling 829 shares during the period. Bbva Compass Bancshares Inc.’s holdings in AbbVie were worth $2,998,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors have also made changes to their positions in the company. Penserra Capital Management LLC acquired a new position in AbbVie in the 4th quarter worth $32,000. Larson Financial Group LLC acquired a new position in AbbVie in the 4th quarter worth $37,000. Horrell Capital Management Inc. acquired a new position in AbbVie in the 4th quarter worth $41,000. Portfolio Solutions LLC acquired a new stake in shares of AbbVie in the 4th quarter valued at about $46,000. Finally, Signet Investment Advisory Group Inc. acquired a new stake in shares of AbbVie in the 4th quarter valued at about $62,000. 70.66% of the stock is owned by hedge funds and other institutional investors.
In other AbbVie news, EVP Azita Saleki-Gerhardt sold 15,797 shares of the company’s stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $79.03, for a total value of $1,248,436.91. Following the completion of the transaction, the executive vice president now owns 93,312 shares in the company, valued at approximately $7,374,447.36. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Vice Chairman Laura J. Schumacher sold 25,000 shares of the company’s stock in a transaction dated Thursday, March 14th. The stock was sold at an average price of $80.00, for a total transaction of $2,000,000.00. Following the completion of the transaction, the insider now owns 139,838 shares of the company’s stock, valued at approximately $11,187,040. The disclosure for this sale can be found here. In the last quarter, insiders have sold 41,272 shares of company stock worth $3,286,290. 0.08% of the stock is owned by company insiders.
ABBV opened at $77.57 on Monday. The stock has a market cap of $114.42 billion, a P/E ratio of 9.81, a price-to-earnings-growth ratio of 1.38 and a beta of 1.16. AbbVie Inc has a fifty-two week low of $75.77 and a fifty-two week high of $107.25.
AbbVie (NYSE:ABBV) last released its quarterly earnings data on Friday, January 25th. The company reported $1.90 earnings per share for the quarter, missing the consensus estimate of $1.92 by ($0.02). The business had revenue of $8.31 billion for the quarter, compared to analyst estimates of $8.37 billion. AbbVie had a negative return on equity of 439.07% and a net margin of 17.36%. AbbVie’s revenue was up 7.3% compared to the same quarter last year. During the same quarter last year, the company earned $1.48 EPS. Analysts expect that AbbVie Inc will post 8.68 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 15th. Investors of record on Monday, April 15th will be paid a dividend of $1.07 per share. The ex-dividend date of this dividend is Friday, April 12th. This represents a $4.28 annualized dividend and a yield of 5.52%. AbbVie’s dividend payout ratio (DPR) is 54.11%.
ABBV has been the topic of a number of recent analyst reports. Bank of America lowered shares of AbbVie from a “buy” rating to a “neutral” rating in a research note on Thursday, January 3rd. Argus lowered shares of AbbVie from a “buy” rating to a “hold” rating in a research note on Monday, March 25th. Standpoint Research initiated coverage on shares of AbbVie in a research note on Wednesday, December 26th. They issued a “buy” rating on the stock. Credit Suisse Group set a $79.00 target price on shares of AbbVie and gave the company a “hold” rating in a research note on Friday, January 25th. Finally, ValuEngine lowered shares of AbbVie from a “hold” rating to a “sell” rating in a research note on Friday, January 25th. Six research analysts have rated the stock with a sell rating, eight have assigned a hold rating and five have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $94.48.
AbbVie Inc discovers, develops, manufactures, and sells pharmaceutical products in the United States, Japan, Germany, Canada, Italy, Spain, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection.
See Also: Ex-Dividend
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.